Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

Clinical trial NCT02916979 · COMPLETED

Trial details

NCT number: NCT02916979
Sponsor: Dartmouth-Hitchcock Medical Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia, Lymphoid Leukemia, Myeloid Myelodysplastic Syndromes Myelofibrosis Lymphoma, Malignant Multiple Myeloma Waldenstrom Macroglobulinemia

Start date: 2016-09-06
Primary completion: 2019-06-07
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.